Median survival time according to response.

Median survival time was 19 months (95% CI, 16.8 months–not reached) for the 70 patients with a sustained response, 6 months (95% CI, 4.3-7.3 months) for the 49 patients with an unsustained response, and only 3 months (95% CI, 2.7-4.7 months) in the 110 patients with no documentation of response during treatment with imatinib.